Daniel O’Day
Chairman and Chief Executive Officer, Gilead Sciences, Inc.
Daniel O'Day is the Chairman of the Board of Directors and Chief Executive Officer at Gilead Sciences.
He joined Gilead in March 2019. Prior to Gilead, Dan served as the Chief Executive Officer of Roche Pharmaceuticals. His career at Roche spanned more than three decades, during which he held a number of executive positions in the company’s pharmaceutical and diagnostics divisions in North America, Europe and Asia. He served as a member of Roche’s Corporate Executive Committee, as well as on a number of public and private boards, including Genentech, Flatiron Health and Foundation Medicine.
Dan holds a bachelor’s degree in biology from Georgetown University and an MBA from Columbia University. He currently serves as the Board Chair for the Pharmaceutical Research and Manufacturers of America (PhRMA) organization. He previously served on the board of directors for Galapagos NV in connection with its partnership with Gilead from 2019 to 2024.
-
Daniel O’Day
Chairman and Chief Executive Officer, Gilead Sciences, Inc.
-
Andrew Dickinson
Chief Financial Officer
-
Stacey Ma
Executive Vice President, Pharmaceutical Development and Manufacturing
-
Flavius Martin, MD
Executive Vice President, Research
-
Jyoti Mehra
Executive Vice President, Human Resources
-
Johanna Mercier
Chief Commercial Officer
-
Merdad Parsey, MD, PhD
Chief Medical Officer
-
Cindy Perettie
Executive Vice President, Kite
-
Deborah H. Telman
Executive Vice President, Corporate Affairs and General Counsel